524-12-9 Usage
Description
Wedelolactone is a member of the coumestan class, characterized by its structure with hydroxy substituents at positions 1, 8, and 9, and a methoxy substituent at position 3. It is a naturally occurring compound with significant biological activities.
Uses
Used in Pharmaceutical Applications:
Wedelolactone is used as an anti-inflammatory agent for its ability to inhibit caspase-11, a key regulator of proinflammatory cytokine IL-1β maturation and apoptosis. This property makes it a potential candidate for the development of treatments targeting inflammatory diseases and conditions.
Used in Cancer Research:
In the field of cancer research, wedelolactone is used as a compound with potential anticancer properties. Its ability to modulate the activity of caspase-11 may contribute to the development of novel therapeutic strategies against various types of cancer.
Used in Drug Delivery Systems:
Similar to gallotannin, wedelolactone can also be incorporated into drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. The development of organic and metallic nanoparticles as carriers for wedelolactone may improve its efficacy in treating various diseases, including cancer and inflammatory conditions.
Biological Activity
wedelolactone is an inhibitor of ikk.ikb kinase (ikk) complex contains the catalytic subunits ikkα and ikkβ, and the regulatory subunit ikkγ/nemo. ikk, is a kinase critical for activation of nf-κb by mediating phosphorylation and degradation of iκbα. the induction of caspase-11 is an important upstream controlling event in inflammatory response and apoptosis under pathological conditions modulated by upstream nf-κb-mediated transcription[1].
Biochem/physiol Actions
Wedelolactone inhibits NF-κB-mediated gene transcription in cells by blocking the phosphorylation and degradation of IκBα. Irreversible inhibitor of IKKα and β kinase activity (IC50 < 10 μM). Wedelolactone has no effects on p38 MAP kinase or Akt.
in vitro
in cultured mouse balb/c 3t3 cells, mouse splenocytes and hela cells, wedelolactone (0~100 μm) inhibited lps-induced caspase-11 expression by inhibiting nf-κb-mediated transcription through the direct inhibition of ikk. wedelolactone played an potential role in anti-inflammatory therapy to inhibit il-1β levels in diseases such as rheumatoid arthritis, asthma and septic shock[1].
in vivo
on swiss albino male mouse skin, ikk inhibition by wedelolactone (10 μm) prevented the induction of nf-κb, perturbed the generation of reactive oxygen species and reactive nitrogen intermediates, blunted the signal transduction that lead to the activation of the early immediate genes, and thereby protected mouse skin from the uvb induced neoplastic transformation, angiotropism and metastatic progression [2].
references
[1] kobori m, yang z, gong d, et al. wedelolactone suppresses lps-induced caspase-11 expression by directly inhibiting the ikk complex.[j]. cell death & differentiation, 2004, 11(1):123-30.[2] ali f, khan b a, sultana s. wedelolactone mitigates uvb induced oxidative stress, inflammation and early tumor promotion events in murine skin: plausible role of nfκb pathway[j]. european journal of pharmacology, 2016, 786:253-264.
Check Digit Verification of cas no
The CAS Registry Mumber 524-12-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 4 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 524-12:
(5*5)+(4*2)+(3*4)+(2*1)+(1*2)=49
49 % 10 = 9
So 524-12-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3
524-12-9Relevant articles and documents
Palladium(II)-catalyzed efficient synthesis of wedelolactone and evaluation as potential tyrosinase inhibitor
Huang, Huidan,Chen, Jianqiu,Ren, Jie,Zhang, Chaofeng,Ji, Fei
, (2019/11/28)
Tyrosinase is an enzyme widely distributed in nature, which has multiple functions, especially in the melanin biosynthesis pathway. Despite the few clinically available tyrosinase inhibitors for whitening, a great demand remains for novel compounds with low side effects in terms of potential carcinogenicity and improved clinical efficacy. A natural product, wedelolactone (WEL), with a polyhydroxyl moiety, attracted our attention as a potential tyrosinase inhibitor. Before we studied the biological activity of the natural product, a synthetic methodological research was firstly carried to obtain enough raw material. WEL could be obtained efficiently through palladium-catalyzed boronation/coupling reactions and 2,3-dicyano-5,6-dichlorobenzoquinone (DDQ)-involved oxidative deprotection/annulation reactions. Immediately after, the natural product was proven to be an efficient tyrosinase inhibitor. In conclusion, we developed a mild and efficient approach for the preparation of WEL, and the natural product was disclosed to have anti-tyrosinase activity, which could be widely used in multiple fields.
Therapeutic drugs for arthritis
-
Page/Page column 7, (2008/06/13)
The present invention relates to the coumestans compounds extracted from Compositae plants, drug compositions or health products comprising the compounds and the use in treatment of rheumatic arthritis or rheumatoid arthritis, osteoarthritis. The animal experiments in vivo or in vitro indicate that the coumestans compounds can effectively treat and alleviate symptoms of rheumatic arthritis or rheumatoid arthritis, and osteoarthritis.
MUSHROOM TYROSINASE CATALYSED SYNTHESIS OF COUMENTANS, BENZOFURAN DERIVATIVES AND RELATED HETEROCYCLIC COMPOUNDS
Pandey, G.,Muralikrishna, C.,Bhalerao, U. T.
, p. 6867 - 6874 (2007/10/02)
Full details of an improved synthesis of coumestan derivatives and their structural analogues, viz., wedelolactone, 11-hydroxy aureol, 11-hydroxy coumestrol along benzofuran derivatives and related heterocyclic systems are reported by coupling of in situ generated o-quinones from catechols catalysed by mushroom tyrosinase with various reatants.